{"title":"卵巢癌PARP抑制剂治疗后急性髓性白血病1例报告并文献复习","authors":"Jing Zeng, Jianrong Wu, Qingli Li, Kemin Li, Danqing Wang, Rutie Yin","doi":"10.21037/gpm-22-34","DOIUrl":null,"url":null,"abstract":"Background: Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPi) are widely used in the maintenance therapy of ovarian cancer. First-line maintenance therapy with PARPi increases overall survival in patients with ovarian cancer. However, the occurrence of rare and delayed adverse events, including cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), should alert researchers and clinicians.","PeriodicalId":92781,"journal":{"name":"Gynecology and pelvic medicine","volume":"41 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acute myeloid leukemia after PARP inhibitor treatment in ovarian cancer—a case report and literature review\",\"authors\":\"Jing Zeng, Jianrong Wu, Qingli Li, Kemin Li, Danqing Wang, Rutie Yin\",\"doi\":\"10.21037/gpm-22-34\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPi) are widely used in the maintenance therapy of ovarian cancer. First-line maintenance therapy with PARPi increases overall survival in patients with ovarian cancer. However, the occurrence of rare and delayed adverse events, including cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), should alert researchers and clinicians.\",\"PeriodicalId\":92781,\"journal\":{\"name\":\"Gynecology and pelvic medicine\",\"volume\":\"41 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecology and pelvic medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/gpm-22-34\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecology and pelvic medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/gpm-22-34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Acute myeloid leukemia after PARP inhibitor treatment in ovarian cancer—a case report and literature review
Background: Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPi) are widely used in the maintenance therapy of ovarian cancer. First-line maintenance therapy with PARPi increases overall survival in patients with ovarian cancer. However, the occurrence of rare and delayed adverse events, including cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), should alert researchers and clinicians.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
